Pfizer Sizes Up Rx Industry; Will Wall Street See Bulk As Strategic Asset?
Executive Summary
Pfizer is heading past the $50 bil. revenue level in 2004, but its biggest challenge may be convincing investors that its staggering size offers a competitive advantage
You may also be interested in...
Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life
Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York
Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
A criminal investigation of Schering-Plough's marketing practices includes off-label promotion, the company disclosed May 30
Cardinal Wants New Deal With Bristol; Inventory Practices Reduce Rx Growth
Cardinal is renegotiating its arrangement with Bristol-Myers Squibb because the wholesaler feels the current deal undervalues its services